文献速递淋巴瘤

整合多组学分析揭示两种具有预后相关性的脾边缘区淋巴瘤亚组

Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance.
PubMed 文献 · Blood Adv · 2026-01-01

本研究通过编码与非编码测序(n=74,含24对肿瘤-正常样本的全基因组测序)及126例患者的DNA甲基化分析,刻画了脾边缘区淋巴瘤(SMZL)的遗传与表观遗传异质性。DNA甲基化分析识别出高危(HR)与低危两个表观遗传亚组,SMZL-HR与不良特征相关,且患者至首次治疗时间(HR=1.9,P=.003)和总生存(HR=2.5,P=.039)显著更差。多因素分析证实SMZL-HR是至首次治疗时间缩短的独立预测因子(HR=2.4,P=.001)。

要点

  • DNA甲基化分析可将SMZL分为高危与低危两个表观遗传亚组。
  • SMZL-HR与女性、IGHV1-2∗04使用、KLF2突变、del(7q)及短端粒等不良特征相关。
  • SMZL-HR是至首次治疗时间缩短的独立预测因子(HR=2.4,P=.001)。

核心结论

  • DNA甲基化与分子谱分析可用于SMZL的风险分层,SMZL-HR亚组预后显著更差。

研究设计与样本

  • 研究采用编码与非编码测序(n=74),包括24对肿瘤-正常样本的全基因组测序、55例靶向测序,并对126例患者进行DNA甲基化分析。

主要发现

  • 全基因组测序识别出KLF2(50%)、KMT2D(25%)、NOTCH2(25%)的复发性克隆性编码突变,以及FLNC(8%)和FAM135B(17%)突变。
  • 非编码突变热点位于BCL6、PAX5和BACH2,与异常体细胞超突变相关,69%的患者至少检测到1个非编码热点。
  • 拷贝数异常见于73%的患者,包括del(7q)(27%)、gain(3q)(17%)和12三体(13%)。
  • DNA甲基化分析识别出高危SMZL(n=67)和低危SMZL(n=59)两个表观遗传亚组。
  • SMZL-HR患者至首次治疗时间显著更短(HR=1.9,P=.003),总生存显著更差(HR=2.5,P=.039);85%的SMZL-HR患者需要治疗,转化频率更高(P=.007),死亡率更高(P<.001)。

关键数值与推荐

  • SMZL-HR与女性、IGHV1-2∗04使用、KLF2突变、del(7q)、短端粒及升高的表观遗传累积有丝分裂评分相关。
  • 转录组分析显示SMZL-HR细胞增殖增强,E2F和G2M检查点通路富集,EZH2介导的表观遗传调控增强。
  • 多因素分析证实SMZL-HR是至首次治疗时间缩短的独立预测因子(HR=2.4,P=.001)。

临床怎么用

  • 对SMZL患者进行DNA甲基化谱分析有助于识别高危亚组,辅助预后评估与治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy with notable genetic, epigenetic, and clinical heterogeneity. In this study, we used coding and noncoding sequencing (n = 74), including whole-genome sequencing (WGS) of 24 paired tumor-normal samples, targeted sequencing (n = 55), and DNA methylation in 126 patients to characterize the disease. From WGS, we identified recurrent, predominantly clonal coding mutations in KLF2 (50%), KMT2D (25%), and NOTCH2 (25%), alongside rare mutations in FLNC (8%), novel mutations in FAM135B (17%), and noncoding mutational hot spots in BCL6, PAX5, and BACH2 linked to aberrant somatic hypermutation. At least 1 noncoding hot spot was detected in 69% of patients. Copy number aberrations were present in 73% of patients, including del(7q) (27%), gain(3q) (17%), and trisomy 12 (13%). DNA methylation profiling revealed 2 epigenetic subgroups: high-risk (HR) SMZL (n = 67) and low-risk SMZL (n = 59). SMZL-HR was associated with adverse features, including female sex, IGHV1-2∗04 usage, KLF2 mutations, del(7q), shorter telomeres, and elevated epigenetically determined cumulative mitoses scores. Transcriptomic analysis highlighted enhanced cell proliferation in SMZL-HR, with enrichment of E2F and G2M checkpoint pathways and epigenetic regulation via EZH2. Patients with SMZL-HR had significantly shorter time to first treatment (TTFT) (hazard ratio, 1.9; P = .003) and reduced overall survival (hazard ratio, 2.5; P = .039): 85% of patients with SMZL-HR required treatment and showed a higher frequency of transformation (P = .007) and mortality (P< .001). Multivariate analysis confirmed SMZL-HR as an independent predictor of shorter TTFT (hazard ratio, 2.4; P = .001). These findings demonstrate the role of DNA methylation and molecular profiling in SMZL risk stratification.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Parker H, Mirandari A, Stevens B, et al. Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance. Blood Adv. 2026. PMID: 42200578. doi:10.1182/bloodadvances.2025019336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。